Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathological characteristics of sonic hedgehog hepatocellular adenomas with special focus on small lesions.

Histopathology·2026
Same author

Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.

Blood cancer journal·2026
Same author

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same author

Secondary <i>BRAF</i>-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma.

Journal of clinical pathology·2026
Same author

Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.

Blood advances·2026
Same author

Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionality.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: May 11, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.

Bettina Bisig1, Aurélien de Reyniès, Christophe Bonnet

  • 1University Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. bettina.bisig@chuv.ch

Haematologica
|May 30, 2013
PubMed
Summary

CD30 expression may distinguish two distinct subtypes of peripheral T-cell lymphoma, not otherwise specified. CD30(+) tumors share molecular and protein features with anaplastic large cell lymphomas and have a better prognosis than CD30(-) types.

More Related Videos

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Related Experiment Videos

Last Updated: May 11, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) is a heterogeneous group of aggressive neoplasms.
  • Previous gene expression profiling identified PTCL, NOS clusters associated with CD30 expression.

Purpose of the Study:

  • To extend molecular profiling of PTCL, NOS to CD30(+) anaplastic large cell lymphomas (ALCL).
  • To validate mRNA expression profiles at the protein level.
  • To assess differences between CD30(+) and CD30(-) PTCL, NOS subgroups.

Main Methods:

  • Reanalysis of existing transcriptomic datasets for PTCL, NOS and ALCL.
  • Immunohistochemical validation of 21 markers on 80 PTCL samples (PTCL, NOS; CD30(+/-); ALCL, ALK(+/-)).
  • Assessment of differences between subgroups and clinical follow-up.

Main Results:

  • CD30(+) PTCL, NOS were enriched in ALK(-) ALCL-related genes compared to CD30(-) tumors.
  • Immunohistochemistry revealed significant differences between CD30(+) and CD30(-) PTCL, NOS, with CD30(+) samples overlapping with ALCL.
  • CD30(-) PTCL, NOS exhibited a trend towards inferior clinical outcome compared to CD30(+) subgroups.

Conclusions:

  • CD30(+) PTCL, NOS share molecular and phenotypic features with ALCL.
  • Significant molecular and phenotypic differences exist between CD30(-) and CD30(+) PTCL, NOS.
  • CD30 expression may delineate two biologically distinct subgroups of PTCL, NOS.